Literature DB >> 21970896

The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme.

Tim R H Read1, Jane S Hocking, Marcus Y Chen, Basil Donovan, Catriona S Bradshaw, Christopher K Fairley.   

Abstract

BACKGROUND: Australia provided free quadrivalent human papillomavirus vaccines to 12-18-year-old girls and women aged ≤26 years from mid-2007 until the end of 2009. After this time, only girls aged 12-13 years had access to free vaccines.
METHODS: Before and after the study, of the proportion of new patients attending Melbourne Sexual Health Centre from mid-2004 to mid-2011, diagnosed with genital warts (GW) by risk group.
RESULTS: From July 2004 to June 2011, 52 454 new patients were seen at Melbourne Sexual Health Centre and 5021 (9.6%, 95% CI 9.3% to 9.8%) were diagnosed with GW. From July 2004 to June 2007, the proportions with GW either increased or did not change in all groups. Comparing the two 12-month periods of 2007/2008 and 2010/2011, GW declined in women under 21 years from 18.6% to 1.9% and in heterosexual men under 21 years from 22.9% to 2.9%. The ORs per year for diagnosis of GW adjusted for number of sexual partners from July 2007 until June 2011 in women and heterosexual men <21 years were 0.44 (95% CI 0.32 to 0.58) and 0.42 (95% CI 0.31 to 0.60), respectively. There was no significant change in GW in women ≥30 years (OR 0.97, 95% CI 0.84 to 1.12), heterosexual men ≥30 years (OR 0.97, 95% CI 0.89 to 1.06) or in homosexual men (OR 0.95, 95% CI 0.85 to 1.07).
CONCLUSION: The dramatic decline and near disappearance of GW in women and men under 21 years of age, 4 years after commencing this programme, suggest that the basic reproductive rate has fallen below one.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21970896     DOI: 10.1136/sextrans-2011-050234

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  56 in total

Review 1.  Human papillomavirus vaccination guideline update: American Cancer Society guideline endorsement.

Authors:  Debbie Saslow; Kimberly S Andrews; Deana Manassaram-Baptiste; Lacey Loomer; Kristina E Lam; Marcie Fisher-Borne; Robert A Smith; Elizabeth T H Fontham
Journal:  CA Cancer J Clin       Date:  2016-07-19       Impact factor: 508.702

2.  Focusing on flu: adolescents' perspectives on school-located immunization programs for influenza vaccine.

Authors:  Mary B Short; Amy B Middleman
Journal:  Hum Vaccin Immunother       Date:  2013-09-09       Impact factor: 3.452

3.  Awareness and Knowledge Levels of Turkish College Students about Human Papilloma Virus Infection and Vaccine Acceptance.

Authors:  Murat Oz; Nilufer Cetinkaya; Aysen Apaydin; Elmas Korkmaz; Sevda Bas; Emre Ozgu; Tayfun Gungor
Journal:  J Cancer Educ       Date:  2018-04       Impact factor: 2.037

Review 4.  Human Papilloma Virus Vaccination and Incidence of Ocular Surface Squamous Neoplasia.

Authors:  Joy N Carroll; Zachary I Willis; Annabelle de St Maurice; Sahar Kohanim
Journal:  Int Ophthalmol Clin       Date:  2017

Review 5.  The burden of human papillomavirus infections and related diseases in sub-saharan Africa.

Authors:  Hugo De Vuyst; Laia Alemany; Charles Lacey; Carla J Chibwesha; Vikrant Sahasrabuddhe; Cecily Banura; Lynette Denny; Groesbeck P Parham
Journal:  Vaccine       Date:  2013-12-29       Impact factor: 3.641

6.  Impact of Number of Human Papillomavirus Vaccine Doses on Genital Warts Diagnoses Among a National Cohort of U.S. Adolescents.

Authors:  Rebecca B Perkins; Mengyun Lin; Sherrie F Wallington; Amresh Hanchate
Journal:  Sex Transm Dis       Date:  2017-06       Impact factor: 2.830

7.  HPV-6 Molecular Variants Association With the Development of Genital Warts in Men: The HIM Study.

Authors:  Ema Flores-Díaz; Karen A Sereday; Silvaneide Ferreira; Bradley Sirak; João Simão Sobrinho; Maria Luiza Baggio; Lenice Galan; Roberto C Silva; Eduardo Lazcano-Ponce; Anna R Giuliano; Luisa L Villa; Laura Sichero
Journal:  J Infect Dis       Date:  2017-02-15       Impact factor: 5.226

8.  Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa.

Authors:  Nelly Mugo; Nana Akosua Ansah; Deborah Marino; Alfred Saah; Elizabeth I O Garner
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 9.  Immunoprevention of human papillomavirus-associated malignancies.

Authors:  Joshua W Wang; Chein-Fu Hung; Warner K Huh; Cornelia L Trimble; Richard B S Roden
Journal:  Cancer Prev Res (Phila)       Date:  2014-12-08

10.  Development and initial feedback about a human papillomavirus (HPV) vaccine comic book for adolescents.

Authors:  Mira L Katz; Benjamin R Oldach; Jennifer Goodwin; Paul L Reiter; Mack T Ruffin; Electra D Paskett
Journal:  J Cancer Educ       Date:  2014-06       Impact factor: 2.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.